NASDAQ
AGIO

Agios Pharm

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Agios Pharm Stock Price

Vitals

Today's Low:
$26.775
Today's High:
$27.47
Open Price:
$26.94
52W Low:
$16.75
52W High:
$34.76
Prev. Close:
$26.87
Volume:
242648

Company Statistics

Market Cap.:
$1.30 billion
Book Value:
20
Revenue TTM:
$14.24 million
Operating Margin TTM:
-2732.07%
Gross Profit TTM:
$12.54 million
Profit Margin:
0%
Return on Assets TTM:
-18.17%
Return on Equity TTM:
-19.38%

Company Profile

Agios Pharm had its IPO on 2013-07-24 under the ticker symbol AGIO.

The company operates in the Healthcare sector and Biotechnology industry. Agios Pharm has a staff strength of 389 employees.

Stock update

Shares of Agios Pharm opened at $26.94 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $26.78 - $27.47, and closed at $27.11.

This is a +0.89% increase from the previous day's closing price.

A total volume of 242,648 shares were traded at the close of the day’s session.

In the last one week, shares of Agios Pharm have slipped by -3.76%.

Agios Pharm's Key Ratios

Agios Pharm has a market cap of $1.30 billion, indicating a price to book ratio of 1.623 and a price to sales ratio of 164.392.

In the last 12-months Agios Pharm’s revenue was $14.24 million with a gross profit of $12.54 million and an EBITDA of $-380483008. The EBITDA ratio measures Agios Pharm's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Agios Pharm’s operating margin was -2732.07% while its return on assets stood at -18.17% with a return of equity of -19.38%.

In Q4, Agios Pharm’s quarterly earnings growth was a positive 0% while revenue growth was a positive 24.3%.

Agios Pharm’s PE and PEG Ratio

Forward PE
2.4655
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-4.04 per share while it has a forward price to earnings multiple of 2.4655 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Agios Pharm’s profitability.

Agios Pharm stock is trading at a EV to sales ratio of 107.3145 and a EV to EBITDA ratio of -2.7625. Its price to sales ratio in the trailing 12-months stood at 164.392.

Agios Pharm stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$1.24 billion
Total Liabilities
$62.63 million
Operating Cash Flow
$82.95 million
Capital Expenditure
$113000
Dividend Payout Ratio
0%

Agios Pharm ended 2024 with $1.24 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.24 billion while shareholder equity stood at $1.10 billion.

Agios Pharm ended 2024 with $0 in deferred long-term liabilities, $62.63 million in other current liabilities, 71000.00 in common stock, $-470561000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $139.26 million and cash and short-term investments were $783.12 million. The company’s total short-term debt was $13,663,000 while long-term debt stood at $0.

Agios Pharm’s total current assets stands at $832.77 million while long-term investments were $313.87 million and short-term investments were $643.86 million. Its net receivables were $2.21 million compared to accounts payable of $18.62 million and inventory worth $8.49 million.

In 2024, Agios Pharm's operating cash flow was $82.95 million while its capital expenditure stood at $113000.

Comparatively, Agios Pharm paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$27.11
52-Week High
$34.76
52-Week Low
$16.75
Analyst Target Price
$37.8

Agios Pharm stock is currently trading at $27.11 per share. It touched a 52-week high of $34.76 and a 52-week low of $34.76. Analysts tracking the stock have a 12-month average target price of $37.8.

Its 50-day moving average was $26.78 and 200-day moving average was $26.39 The short ratio stood at 10.99 indicating a short percent outstanding of 0%.

Around 135% of the company’s stock are held by insiders while 10776.4% are held by institutions.

Frequently Asked Questions About Agios Pharm

The stock symbol (also called stock or share ticker) of Agios Pharm is AGIO

The IPO of Agios Pharm took place on 2013-07-24

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$87.3
-6
-6.43%
$2
0.14
+7.53%
$10.07
-0.06
-0.59%
Glencore PLC (GLCNF)
$5.4
0.15
+2.86%
$25.33
0.05
+0.2%
$0.06
0
0%
$22.38
0.75
+3.47%
$314.75
-19.1
-5.72%
$0.04
0
+5.25%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Address

88 Sidney Street, Cambridge, MA, United States, 02139-4169